Cargando…

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response

The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61–80 years of age with newly diagnosed CD20(+) diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ≥2). Patients receive standard chemotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denker, Sophy, Bittner, Aitomi, Na, Il-Kang, Kase, Julia, Frick, Mareike, Anagnostopoulos, Ioannis, Hummel, Michael, Schmitt, Clemens A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939221/ https://www.ncbi.nlm.nih.gov/pubmed/31903182 http://dx.doi.org/10.2217/ijh-2019-0010

Ejemplares similares

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

CHOP links endoplasmic reticulum stress to NF-κB activation in the pathogenesis of nonalcoholic steatohepatitis
por: Willy, Jeffrey A., et al.
Publicado: (2015)

Type 2 Diabetes Is Associated with Altered NF-κB DNA Binding Activity, JNK Phosphorylation, and AMPK Phosphorylation in Skeletal Muscle after LPS
por: Andreasen, Anne Sofie, et al.
Publicado: (2011)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
por: Rodríguez, Manuel, et al.
Publicado: (2017)

A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
por: Arcari, Annalisa, et al.
Publicado: (2023)

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
por: Davies, Andrew J., et al.
Publicado: (2023)

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

NF-κB and Disease
por: Poma, Paola
Publicado: (2020)

NF-κB Inhibitors from Eurycoma longifolia
por: Tran, Thi Van Anh, et al.
Publicado: (2014)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

NF-κB Members Left Home: NF-κB-Independent Roles in Cancer
por: Colomer, Carlota, et al.
Publicado: (2017)

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2021)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
por: Jayawant, Eleanor, et al.
Publicado: (2023)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

NF-κB Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-κB Function in Normal B Cells
por: Pasqualucci, Laura, et al.
Publicado: (2022)

Analysis of variation in NF-κB genes and expression levels of NF-κB-regulated molecules
por: Liu-Mares, Wen, et al.
Publicado: (2007)

NF-κB and the Immunoglobulin κ Gene Enhancer
por: Sen, Ranjan
Publicado: (2004)

Keeping NF-κB in check
por: Williams, Ruth
Publicado: (2006)

At the crossroads of SUMO and NF-κB
por: Kracklauer, Martin P, et al.
Publicado: (2003)

Slow but steady for NF-κB
por: Leslie, Mitch
Publicado: (2012)

NF-κB in premature aging
por: Osorio, Fernando G., et al.
Publicado: (2012)

Hypoxia Induced NF-κB
por: D’Ignazio, Laura, et al.
Publicado: (2016)

NF-κB signaling in inflammation
por: Liu, Ting, et al.
Publicado: (2017)

Noncanonical NF-κB in Cancer
por: Tegowski, Matthew, et al.
Publicado: (2018)

NFκB and Kidney Injury
por: Song, Ning, et al.
Publicado: (2019)

NF-κB in Hematological Malignancies
por: Imbert, Véronique, et al.
Publicado: (2017)

NF-κB Signalling in Glioblastoma
por: Soubannier, Vincent, et al.
Publicado: (2017)

To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator
por: Sorriento, Daniela, et al.
Publicado: (2012)

Diacerein modulates TLR4/ NF‐κB/IL‐1β and TRPC1/CHOP signalling pathways in gentamicin‐induced parotid toxicity in rats
por: Ali, Dalia Mohamed, et al.
Publicado: (2023)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dd9fgogpj8tc2lj0lvq9e3qvh8